Masimo Co. (NASDAQ:MASI) Shares Sold by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. decreased its holdings in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 39.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,924 shares of the medical equipment provider's stock after selling 2,529 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.'s holdings in Masimo were worth $672,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in Masimo by 76.4% in the third quarter. BNP Paribas Financial Markets now owns 19,982 shares of the medical equipment provider's stock valued at $2,664,000 after acquiring an additional 8,656 shares in the last quarter. Verition Fund Management LLC purchased a new stake in Masimo during the 3rd quarter worth $245,000. Edgestream Partners L.P. lifted its holdings in Masimo by 103.9% in the 3rd quarter. Edgestream Partners L.P. now owns 10,449 shares of the medical equipment provider's stock worth $1,393,000 after buying an additional 5,325 shares in the last quarter. Centiva Capital LP acquired a new stake in shares of Masimo during the third quarter valued at about $678,000. Finally, Stifel Financial Corp purchased a new stake in shares of Masimo during the third quarter worth about $229,000. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Stock Performance

MASI traded up $5.96 during trading hours on Monday, hitting $150.36. The company's stock had a trading volume of 1,133,100 shares, compared to its average volume of 645,075. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The company has a 50-day simple moving average of $173.23 and a 200 day simple moving average of $163.63. The firm has a market capitalization of $8.12 billion, a PE ratio of 103.70 and a beta of 1.28.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. The business had revenue of $600.70 million for the quarter, compared to analysts' expectations of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. As a group, sell-side analysts expect that Masimo Co. will post 4.1 EPS for the current year.

Insider Transactions at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now directly owns 16,581 shares of the company's stock, valued at $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares in the company, valued at approximately $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.70% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on MASI shares. Wells Fargo & Company lifted their price objective on Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Piper Sandler boosted their target price on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Raymond James lifted their price target on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research note on Friday, December 27th. Finally, Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $194.80.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.